Invesco DB Oil Fund vs GeneDx Holdings Corp — how do they compare? Invesco DB Oil Fund trades at $19.88, while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Invesco DB Oil Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| DBO | WGS | |
|---|---|---|
Sector | Commodities - Energy | Technology |
52-Week High | $23.80 | $167.51 |
52-Week Low | $11.98 | $34.51 |
Market Cap | — | $1.85B |
Enterprise Value | — | $1.85B |
Signals from Pluang's Aura AI — not financial advice
DBO is trading at $19.59, up 8.47% with strong bullish momentum driven by escalating Middle East tensions that are boosting oil prices. Technical indicators show a bullish trend with support at $19 and resistance at $20, though RSI suggests potential overbought conditions. The stock benefits from geopolitical events that typically drive energy sector performance.
The outlook remains positive as oil price strength translates to potential revenue growth for US energy companies. Key risks include geopolitical volatility and potential supply disruptions. Analyst sentiment appears constructive given the favorable oil market dynamics, though fundamental metrics require verification from recent SEC filings.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Trailing returns across standard periods
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →